IN2015DN01706A - - Google Patents

Download PDF

Info

Publication number
IN2015DN01706A
IN2015DN01706A IN1706DEN2015A IN2015DN01706A IN 2015DN01706 A IN2015DN01706 A IN 2015DN01706A IN 1706DEN2015 A IN1706DEN2015 A IN 1706DEN2015A IN 2015DN01706 A IN2015DN01706 A IN 2015DN01706A
Authority
IN
India
Prior art keywords
achei
increasing
pharmaceutical composition
high dose
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Smith Kathleen E Clarence
Thomas N Chase
Original Assignee
Chase Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Pharmaceuticals Corp filed Critical Chase Pharmaceuticals Corp
Publication of IN2015DN01706A publication Critical patent/IN2015DN01706A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IN1706DEN2015 2012-09-05 2013-09-05 IN2015DN01706A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261697069P 2012-09-05 2012-09-05
US201261697021P 2012-09-05 2012-09-05
US201261696978P 2012-09-05 2012-09-05
US201261697039P 2012-09-05 2012-09-05
PCT/US2013/058172 WO2014039627A1 (fr) 2012-09-05 2013-09-05 Composition et procédés neuroprotecteurs anticholinergiques

Publications (1)

Publication Number Publication Date
IN2015DN01706A true IN2015DN01706A (fr) 2015-05-22

Family

ID=50237591

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1706DEN2015 IN2015DN01706A (fr) 2012-09-05 2013-09-05

Country Status (14)

Country Link
US (4) US9561218B2 (fr)
EP (2) EP4035668A1 (fr)
JP (4) JP2015531346A (fr)
KR (2) KR20200065113A (fr)
CN (1) CN104768540A (fr)
AU (1) AU2013312749B2 (fr)
BR (3) BR122016020434A2 (fr)
CA (1) CA2882407C (fr)
EA (1) EA038489B1 (fr)
HK (1) HK1210947A1 (fr)
IL (3) IL237176B (fr)
IN (1) IN2015DN01706A (fr)
MX (2) MX385976B (fr)
WO (1) WO2014039627A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969402B2 (en) * 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
PT3061821T (pt) 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
MX356386B (es) * 2012-08-09 2018-05-28 Chase Pharmaceuticals Corp Sales cuaternarias de piperidinio.
EP4035668A1 (fr) * 2012-09-05 2022-08-03 Chase Pharmaceuticals Corporation Composition et procédés neuroprotecteurs anticholinergiques
EP4122460A1 (fr) * 2015-01-09 2023-01-25 Chase Pharmaceuticals Corporation Système combiné thérapeutique transdermique d'oxybutynine
CA2978201A1 (fr) 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Utilisation de formulations transdermiques d'oxybutynine pour reduire les effets secondaires associes aux agonistes muscariniques
US10307409B2 (en) 2015-03-06 2019-06-04 Chase Pharmaceuticals Corporation Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
US20180360845A1 (en) * 2015-07-20 2018-12-20 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
EP3347012A4 (fr) * 2015-09-11 2019-04-17 Chase Pharmaceuticals Corporation Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
US20180250270A1 (en) * 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
US10357487B2 (en) * 2015-12-03 2019-07-23 Sidney J. Goldfarb Combinations of acetylcholinesterase inhibitors and muscarinic agonists and methods of use thereof
WO2017147104A1 (fr) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Combinaisons d'antagoniste muscarinique m2
US10548855B2 (en) * 2016-10-28 2020-02-04 Chase Pharmaceuticals Corporation Memantine combinations and use
CA3071377C (fr) 2017-01-09 2021-11-30 Kathleen E. Clarence-Smith Compositions et methodes pour ameliorer une faiblesse dans les muscles des patients souffrant de myasthenie grave et d'autres syndromes de myasthenie
US20200000756A1 (en) * 2017-01-24 2020-01-02 Gt Biopharma, Inc. Neostigmine combination and compositions
IL269550B2 (en) 2017-03-27 2025-01-01 Chase Therapeutics Corp Combining a 5HT3 antagonist and pramipexole for the treatment of synucleinopathies
KR102408292B1 (ko) 2018-09-28 2022-06-10 카루나 세러퓨틱스 인코포레이티드 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법
US12112463B2 (en) 2020-09-14 2024-10-08 City University Of Hong Kong Method, device and computer readable medium for intrinsic popularity evaluation and content compression based thereon
US11759451B2 (en) 2020-09-15 2023-09-19 City University Of Hong Kong Therapeutic potential of glycopyrrolate and mexiletine for nervous system injury
US12109202B2 (en) * 2021-01-29 2024-10-08 Qaam Pharmaceuticals, Llc Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders
US20220304946A1 (en) * 2021-03-28 2022-09-29 Muhammad Imran Khan Trans-anethole ((e)-1-methoxy-4- (1-propenyl) benzene), a new and potent inhibitor of prolyl endopeptidase

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3480626A (en) 1967-05-18 1969-11-25 Chem Fab Dr R Pfleger Certain azoniaspironortropine derivatives
GB1204580A (en) 1968-10-05 1970-09-09 Aspro Nicholas Ltd Pharmaceutical dosage forms
US3576388A (en) 1968-12-05 1971-04-27 Stauffer Wacker Silicone Corp Electrical cable
DD106643A1 (fr) 1973-07-12 1974-06-20
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
GB9423588D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
CZ297533B6 (cs) 1997-07-09 2007-01-03 Axonyx Použití inhibitorů butyrylcholinesterázy pro léčbu a diagnostiku Alzheimerovy choroby a demence
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
EP0976404A3 (fr) 1998-07-30 2001-06-27 Pfizer Products Inc. Compositions pharmaceutiques pour la prévention et la therapie de troubles cognitifes chez les mammifères
BR9914251A (pt) 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
CN1285348A (zh) 1999-08-20 2001-02-28 广东康美药业股份有限公司 盐酸丙哌维林合成工艺
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
AU2002253929A1 (en) 2001-02-08 2002-09-24 Schering Corporation Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
US7427280B2 (en) 2002-09-06 2008-09-23 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues
CN1520818A (zh) 2003-02-09 2004-08-18 ɽ����Ҷ��Ȼҩ���о��������޹�˾ 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
KR100510788B1 (ko) 2003-07-22 2005-08-26 동방에프티엘 주식회사 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법
KR100500760B1 (ko) 2003-07-22 2005-07-14 동방에프티엘 주식회사 염산 프로피베린의 제조방법
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
ES2330451T3 (es) 2004-01-16 2009-12-10 Wyeth Inhibidores a base de sulfonamidas heterociclicas de la produccion de beta-amiloides que contienen un azol.
AR051950A1 (es) 2004-11-10 2007-02-21 Osmotica Pharmaceutical Argent Comprimido multicapa con capas que se separan
EP1861361A1 (fr) * 2005-03-24 2007-12-05 Sosei R&D Ltd. Sels de glycopyrronium et leur application thérapeutique
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
US20070224259A1 (en) 2005-09-21 2007-09-27 Gupta Anil K Anti-inflammatory pharmaceutical composition
US20070093519A1 (en) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Anti-emetic uses of cannabinoid analogs
WO2007055806A1 (fr) * 2005-10-31 2007-05-18 Indevus Pharmaceuticals, Inc. Utilisation antiemetique des acides (3r,4r)-δ8-tetrahydrocannabinol-11-oiques
CA2630846A1 (fr) 2005-12-21 2007-07-05 Teva Pharmaceutical Industries Ltd. Procedes de preparation de solifenacine
JP2009534385A (ja) 2006-04-21 2009-09-24 ワイス キラル的に純粋なアミノアルコール中間体、それらの誘導体の製造、及びそれらの使用
DE602007013559D1 (de) 2006-07-07 2011-05-12 Univ Aarhus Nanoteilchen zur abgabe von nukleinsäure
US8097633B2 (en) 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
EP4088717A1 (fr) * 2008-03-27 2022-11-16 Chase Pharmaceuticals Corporation Association d'un nspacha (agent anticholinergique peripherique) comme la solifenacine et d'un achei (inhibiteur de l'acetyl choline esterase) comme le donepezil pour traiter la demence
US20110201597A1 (en) * 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
WO2009139002A2 (fr) 2008-05-12 2009-11-19 Msn Laboratories Limited Procédé perfectionné de fabrication de solifénacine et de ses sels pharmaceutiquement acceptables
WO2011003624A1 (fr) 2009-07-09 2011-01-13 Krka, D.D., Novo Mesto Procédé pour la préparation et la purification de sels de solifénacine
MX345236B (es) * 2009-09-18 2017-01-23 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.
EP2470504B1 (fr) 2010-03-15 2013-10-16 Ramesha Andagar Ramakrishna Synthèse de chlorhydrate de propivérine
EP2554184B1 (fr) * 2010-03-31 2016-10-26 ONO Pharmaceutical Co., Ltd. Agent préventif et/ou remède pour le syndrome d'enflure douloureuse des mains et des pieds
KR101149821B1 (ko) 2010-04-05 2012-05-24 하나제약 주식회사 디페닐아세테이트 유도체의 새로운 제조방법
US8772491B2 (en) 2010-06-28 2014-07-08 Aurobindo Pharma Ltd Process for the preparation of solifenacin succinate
CN102218063B (zh) 2011-04-12 2013-03-13 贵州神奇制药有限公司 盐酸丙哌维林药物的制备方法和产品及其检测方法
EP4035668A1 (fr) * 2012-09-05 2022-08-03 Chase Pharmaceuticals Corporation Composition et procédés neuroprotecteurs anticholinergiques

Also Published As

Publication number Publication date
US20190000826A1 (en) 2019-01-03
HK1210947A1 (en) 2016-05-13
IL268603B (en) 2021-03-25
EP2892514A1 (fr) 2015-07-15
IL237176B (en) 2018-02-28
MX385976B (es) 2025-03-18
JP2015531346A (ja) 2015-11-02
US9561218B2 (en) 2017-02-07
BR112015004902A2 (pt) 2017-07-04
US20170087142A1 (en) 2017-03-30
JP2021191759A (ja) 2021-12-16
CA2882407A1 (fr) 2014-03-13
US20190365736A1 (en) 2019-12-05
CA2882407C (fr) 2022-11-15
KR20200065113A (ko) 2020-06-08
MX2015002864A (es) 2015-07-14
AU2013312749A2 (en) 2015-04-16
IL237176A0 (en) 2015-04-30
IL257150A (en) 2018-03-29
IL268603A (en) 2019-10-31
US20150231122A1 (en) 2015-08-20
EA201500293A1 (ru) 2015-07-30
EP2892514A4 (fr) 2016-04-13
JP2020105212A (ja) 2020-07-09
MX2020002113A (es) 2021-09-08
WO2014039627A1 (fr) 2014-03-13
JP2018150314A (ja) 2018-09-27
AU2013312749A1 (en) 2015-04-02
EA038489B1 (ru) 2021-09-06
BR122016020434A2 (pt) 2019-08-27
EP4035668A1 (fr) 2022-08-03
KR20150048888A (ko) 2015-05-07
AU2013312749B2 (en) 2018-01-18
CN104768540A (zh) 2015-07-08
BR122016020433A2 (pt) 2019-08-27
US9913836B2 (en) 2018-03-13
MX378091B (es) 2025-03-10

Similar Documents

Publication Publication Date Title
IN2015DN01706A (fr)
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
WO2014028597A3 (fr) Composés indazole et indole à substitution cyclohexyl et 3-cyclohexenyl
NZ708593A (en) Novel pyrazole derivative
IN2014MN01755A (fr)
NZ703064A (en) Inhibitors of hepatitis c virus
MX344177B (es) Uso y composicion para tratar la demencia.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
PH12013502677A1 (en) Benzylamine derivatives as inhibitors of plasma kallikrein
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
MX2014003080A (es) Inhibidores sustituidos de n-[1-ciano-2- (fenil) etil]-2-azabiciclo[2.2.1] heptan-3-carboxamida de catepsina c.
IN2015DN01156A (fr)
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
NZ706739A (en) Substituted benzene compounds
IN2014DN10386A (fr)
CA2773592C (fr) Methode et composition pour traiter la demence du type alzheimer
IN2014MN02652A (fr)
PH12014502757A1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
IN2014KN01075A (fr)
IN2014MN01962A (fr)
MY169485A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
NZ603625A (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
IN2013DN02555A (fr)